| Name | Title | Contact Details |
|---|
Green Tree School and Services (GTSS) is a nonprofit, state-licensed agency that provides education, therapeutic and clinical support to children ages 5-21 with Autism Spectrum Disorder and Severe Emotional Disability. GTSS only serves children whose disabilities are such that they are unable to succeed in a school- based special education program or participate in out of school activities. Rates of both diagnosis are growing, with 1 in 68 children currently affected by Autism and 1 in 78 children affected by Emotional Disability. GTSS’ philosophy is rooted in the belief that every child should have the opportunity to learn the academic, social, emotional, and vocational and life skills they need to achieve resiliency and succeed in their learning, living and working environments. GTSS has worked with children and young adults with special needs since 1957, marking over a half century of Transforming Lives and Impacting Communities. GTSS offers a variety of on-site and off-site services to children with special needs, both directly and through their home school or district. The Approved Private School educates children whose disabilities prevent them from succeeding in a traditional special education program. Specialists work with children, in small groups or individually, to help students meet individual goals. The Outpatient Clinic provides psychiatric evaluation, case management and medication management services to students at the school. Consulting Services, also called Green Tree Partnerships, is an education consulting cooperative created by GTSS. Staff work collaboratively with a school or district and take on the management of portion of that school or district’s special education program. Students who exhibit signs of autism or emotional disabilities, but do not have a complete or up to date Individual Educational Plan, can receive Diagnostic Services from GTSS.
As a company, we believe in digital health for everyone everywhere. We have created a new category of therapeutic product – the digital health feedback system – to allow people of all ages and cultures to power their own health, taking better care of themselves and each other. We see two trends: First, there are more people with mobile phones than there are with access to clean, running water. Second, chronic, often lifestyle-related diseases like diabetes are the world’s biggest healthcare problem, and our health systems can’t cope because they are optimized to treat the acute conditions prevalent decades ago. Our vision is to integrate medicines that treat chronic conditions with mobile technology – via our ingestible sensor – to make healthcare more accessible, manageable and innovative. We believe that by providing the right technology to individuals who deliver and receive healthcare, we can build a more effective healthcare system with new care paradigms focused on daily care and new information-based business models.
Teleflex Medical OEM is a Kenosha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bottom Line Benefits is a Acworth, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN". The Company`s principal executive offices are located in Rockville, MD, and the finance and administrative office is located in Ann Arbor, MI. Synthetic Biologics, Inc. is a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases. The Company`s lead candidates in Phase 2 development include SYN-004 which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection and antibiotic-associated diarrhea (AAD), and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat the underlying cause of irritable bowel syndrome with constipation (IBS-C). In addition, the Company is developing a monoclonal antibody combination for the treatment of Pertussis, and a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.